Inmed Pharmaceuticals Granted U.S. Patent #12042479 Use Of Topical Formulations Of Cannabinoids In The Treatment Of Epidermolysis Bullosa And Related Connective Tissue Disorders
Portfolio Pulse from charles@benzinga.com
Inmed Pharmaceuticals has been granted U.S. Patent #12042479 for the use of topical formulations of cannabinoids in the treatment of Epidermolysis Bullosa and related connective tissue disorders.
July 23, 2024 | 2:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inmed Pharmaceuticals has received a U.S. patent for its cannabinoid-based topical formulations aimed at treating Epidermolysis Bullosa and related connective tissue disorders. This patent could enhance the company's market position and product portfolio.
The granting of a U.S. patent for a specific medical application can significantly enhance Inmed Pharmaceuticals' market position and product portfolio. This development is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100